Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform

Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.

3d illustration of T cells or cancer cells

Gilead Sciences Inc. chose to invest up to $3.16bn in one of the gene editing field's earliest developers – Sangamo Therapeutics Inc. – over emerging players in this area to help Gilead's Kite Pharma Inc. subsidiary create better T cell therapies for cancer.

Gilead executives have said since the company acquired chimeric antigen receptor T cell (CAR-T) therapy developer Kite for $11.9bn last year it would invest in additional technologies to expand and improve its new cell therapy platform. Gilead President and CEO John Milligan described Sangamo's zinc finger nuclease (ZFN) technology as "the optimal gene editing platform," in a Feb

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Industry Leaders Grapple With Trump’s MFN Pricing Plan

14 May 2025

• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.